ELEVANCE HEALTH, INC. financials

ELV CIK 0001156039

Source: EDGAR filings · Built 2026-06-19T02:19:47Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 3.17B 4.55B 6.76B 7.25B 7.28B 9.67B
EBITDA 8.74B 9.26B 10.24B 9.96B 8.86B 7.51B
Working Capital 21.97B 18.36B 18.24B 15.92B 16.24B 16.30B
Net Debt 23.21B 23.75B 19.44B 17.66B 21.84B 18.77B
Gross Margin 89.36% 88.84% 89.91% 91.68% 92.14% 92.65%
Operating Margin 3.62% 4.44% 4.96% 5.29% 5.45% 5.22%
Net Margin 2.84% 3.38% 3.49% 3.76% 4.44% 3.75%
Return on Equity (ROE) 12.90% 14.47% 15.23% 16.26% 17.06% 13.77%
Return on Assets (ROA) 4.66% 5.12% 5.50% 5.74% 6.32% 5.28%
Current Ratio 1.54× 1.45× 1.44× 1.40× 1.47× 1.55×
Debt-to-Equity 0.75× 0.78× 0.66× 0.69× 0.74× 0.74×
Effective Tax Rate 15.63% 24.46% 22.35% 22.53% 23.09% 26.71%
Cash Conversion Ratio 0.76× 0.97× 1.35× 1.43× 1.36× 2.34×
Accruals Ratio 0.01× 0.00× -0.02× -0.02× -0.02× -0.07×
SBC % of Revenue 0.14% 0.11% 0.17% 0.17% 0.18% 0.23%
CapEx Coverage 3.84× 4.62× 6.22× 7.29× 7.69× 10.47×
Free Cash Flow Per Share $14.13 $19.54 $28.50 $29.85 $29.49 $38.01

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenues 199.13B 177.01B 171.34B 156.59B 138.64B 121.87B
Cost of Goods and Services Sold 21.18B 19.75B 17.29B 13.04B 10.89B 8.95B
Selling, General and Administrative Expense 20.98B 20.02B 20.09B 17.70B 15.92B 17.45B
Operating Income (Loss) 7.20B 7.86B 8.50B 8.28B 7.56B 6.36B
Income Tax Expense (Benefit) 1.05B 1.93B 1.72B 1.71B 1.85B 1.67B
Net Income (Loss) Attributable to Parent 5.66B 5.98B 5.99B 5.89B 6.16B 4.57B
Earnings Per Share, Basic $25.28 $25.81 $25.38 $24.56 $25.26 $18.23
Weighted Average Number of Shares Outstanding, Basic 224.00M 231.70M 235.90M 240.00M 243.80M 250.80M
Earnings Per Share, Diluted $25.21 $25.68 $25.22 $24.28 $24.95 $17.98
Weighted Average Number of Shares Outstanding, Diluted 224.60M 232.90M 237.40M 242.80M 246.80M 254.30M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 9.49B 8.29B 6.53B 7.39B 4.88B 5.74B
Assets, Current 63.00B 58.94B 60.03B 55.62B 51.12B 45.75B
Assets 121.49B 116.89B 108.93B 102.75B 97.46B 86.61B
Long-term Debt 31.90B 30.87B 24.89B 23.85B 22.76B 20.04B
Liabilities, Current 41.03B 40.58B 41.79B 39.70B 34.88B 29.45B
Long-term Debt, Excluding Current Maturities 30.80B 29.22B 23.25B 22.35B 21.16B 19.34B
Liabilities 77.47B 75.46B 69.52B 66.42B 61.29B 53.42B
Stockholders' Equity Attributable to Parent 43.88B 41.31B 39.31B 36.24B 36.09B 33.20B
Common Stock, Shares, Outstanding 220.72M 227.48M 233.07M 237.96M 241.77M 245.40M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 4.29B 5.81B 8.06B 8.40B 8.36B 10.69B
Payments to Acquire Property, Plant, and Equipment 1.12B 1.26B 1.30B 1.15B 1.09B 1.02B
Net Cash Provided by (Used in) Investing Activities -1.34B -5.17B -5.57B -4.56B -9.64B -7.32B
Payments for Repurchase of Common Stock 2.60B 2.90B 2.68B 2.32B 1.90B 2.70B
Payments of Dividends 1.53B 1.51B 1.40B 1.23B 1.10B 954.00M
Net Cash Provided by (Used in) Financing Activities -1.74B 1.19B -3.35B -1.32B 423.00M -2.57B

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ELV CIK 0001156039), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

INCY

INCYTE CORPORATION

SYK

STRYKER CORP

CAH

Cardinal Health, Inc.